Document:

Unassociated Document

    EXHIBIT
10.9

    

    June __,
2004

    
 

    BioLineRx
Ltd.

    Hartum
Street

    P.O. Box
45158

    Jerusalem,
91450

    Israel

    Attn:  CEO

    

    Dear
Sirs,

    

    
      	
               
      

            	
              Re:

            	
              First Amendment of
      Research and License Agreement, Dated April 15, 2004, by and Among
      BioLineRX Ltd., Ramot at Tel Aviv University, Ltd and Bar-Ilan Research
      and Development Company Ltd. the
  "Agreement")

            

    

    
       

    

    You have brought to our attention the
fact that Section 9.1.1 of the Agreement (Licensor Confidential Information) has
created a problem with respect to your ability to enter into agreements with
potential contractors/collaborators and to attract
investors.  Specifically, the provision states that your obligations
of confidentiality and non-use (other than for the purposes of the Agreement)
remain in effect during the term of the agreement, and for five (5) years
thereafter.  As you have explained to us, potential
contractors/collaborators are unwilling to be bound by such confidentiality and
non-use obligations with respect to the Confidential Information (as defined in
the Agreement) for such undefined term.  Therefore, in order to enable
you to continue to develop Licensed Product (as defined in the Agreement) and to
exercise your rights and fulfill your obligations under the Agreement, we hereby
agree to amend the agreement as follows, effective immediately:

    

    The
following shall be inserted at the end of Section 9.1.1:

    

    "Notwithstanding
anything to the contrary in this Section 9.1.1, Bioline may disclose
Licensor Confidential Information to actual and potential business partners,
collaborators, investors, contractors, service providers and consultants,
provided, in each case, that such recipient of Confidential Information first
enters into a legally binding agreement with BioLine which imposes
confidentiality and non-use obligations with respect to Confidential Information
comparable to those set forth in this Agreement for a period of least five (5)
from the date of disclosure of Licensor Confidential Information to such
recipient."

    

    All other
provisions of the Agreement shall remain unchanged.

    

    Please
indicate your agreement to the above amendment to the Agreement by signing
below.

    

    
      
        
          
            
              
                
                  
                    
                      	 
      	 
      	
                              Sincerely,

                            
	 
      	 
      	 
      
	
                              Ramot
      at Tel Aviv University Ltd.

                            	 
      	
                              Bar-Ilan
      Research and Development

                            
	 
      	 
      	
                              Company
      Ltd.

                            
	 
      	 
      	 
      
	
                              By:

                            	      
                              /s/
      ISAAC KOHLBERG

                            	 
      	
                              By:

                            	      
                              /s/
      GABRIEL KENAN

                            
	 
      	 
      	 
      	 
      	 
      
	
                              Name: 

                            	      
                              ISAAC
      KOHLBERG

                            	 
      	
                              Name: 

                            	      
                              GABRIEL
      KENAN

                            
	 
      	 
      	 
      	 
      	 
      
	
                              Title:

                            	      
                              CEO

                            	 
      	
                              Title:

                            	      
                              CEO

                            

                    

                  

                

              

            

          

        

      

    

    

    Agreed
to and Accepted:

    

    BioLineRx
Ltd.

    

    
      
        	
                By:
      

              	
                /s/ Yuri Shoshan   /s/ Morris
    Laster

              	 
      
	 
      	 
      	 
      
	
                Name: 

              	
                Yuri
      Shoshan           Morris Laster

              	 
      
	 
      	 
      	 
      
	
                Title:

              	
                VP
      Finance           CEOEXHIBIT
10.10

    

    AMENDMENT
AGREEMENT

    

    THIS
AMENDMENT AGREEMENT, dated as of the 20th day of December, 2005, (the “Effective Date”), is entered
into by and between BioLineRx Ltd. (“BioLine”), Bar-Ilan Research
and Development Company Ltd. (“BIRAD”) and Ramot at Tel Aviv
University Ltd. (“Ramot”, and together with
BIRAD, the “Licensors”).

    

    WHEREAS,
BioLine and the Licensors entered into that certain Research and License
Agreement dated as of April 15, 2004 (the “Research and License
Agreement”); and

    

    WHEREAS,
the parties desire to amend the Research and License Agreement as set out
herein;

    

    NOW,
THEREFORE, the parties agree as follows:

    

    1.   
        Capitalized terms used but not
otherwise defined herein shall have the meanings ascribed to them in the
Research and License Agreement.

    

    2.    
       Section 13.4.3 of the Resarch and
License Agreement shall be deleted in its entirety and replaced with the
following:

    

    “13.4.3. Transfer of Regulatory
Filings and Know How.  In the event BioLine terminates this
Agreement pursuant to Section 13.3.1 or Ramot terminates this Agreement pursuant
to Section 6.4, 13.3.2 or 13.3.3 (except in the circumstances set out in Section
13.3.3.2), BioLine shall promptly deliver and assign to Licensors (a) all
documents and other materials filed by or on behalf of BioLine and its
Affiliates with Regulatory Agencies in furtherance of applications for
Regulatory Approval in the relevant country with respect to Licensed Products;
and (b) all intellectual property, inventions, conceptions, compositions,
materials, methods, processes, data, information, records, results, studies and
analyses, discovered or acquired by, or on behalf of BioLine and its Affiliates
which relate directly to actual or potential Licensed Products; provided, however, that to the
extent that any of the items set forth in clauses (a) or (b) were developed
using funds granted by the Office of Chief Scientist of the Israel Ministry of
Industry, Trade and Labor (the “OCS”), such items are and remain subject to the
rules and regulations of the OCS, including without limitation, the Law for the
Encouragement of Industrial Research & Development, 1984.  The
Licensors, the TAU Team and the BIU Team shall be entitled to freely use and to
grant others the right to use all such materials, documents and know-how
delivered pursuant to this 13.4.3.”

    

    3.        
   Except as amended pursuant to this Amendment Agreement, the
terms of the Research and License Agreement shall remain in full force and
effect.

    

    [Remainder
of page intentionally left blank.  Signature page
follows.]

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    IN WITNESS WHEREOF, the
parties have caused this Agreement to be executed by their duly authorized
representatives as of the date first written above.

    

    
      
        
          
            
              
                
                  	
                          Ramot
      at Tel Aviv University Ltd.

                        	 
      	
                          BioLineRx
      Ltd.

                        
	 	 	 
	
                          By:
      /s/ Ze’ev Weinfeld, Ph.D.

                        	 
      	
                          By:
      /s/ Yuri
      Shoshan

                        
	 	 	 
	
                          Name:
      Ze’ev Weinfeld, Ph.D.

                        	 
      	
                          Name:
      Yuri Shoshan

                        
	 	 	 
	
                          Title:
      Executive Vice President

                        	 
      	
                          Title:
      Vice President

                        
	
                                
         Business Development

                        	 
      	
                          Finance
      and Corporate Development

                        
	 
      	 
      	 
      
	
                          Bar-Ilan
      Research and Development Company Ltd.

                        	 
      	 
      
	 
      	 
      	 
      
	
                          By:
      /s/ Gabriel Kenan

                        	 
      	 
      
	 	 	 
	
                          Name:Gabriel
      Kenan

                        	 
      	 
      
	 	 	 
	
                          Title:
      CEOEXHIBIT
10.11

    

    AMENDMENT
AGREEMENT

    

    THIS
AMENDMENT AGREEMENT, dated as of the 7th day of March, 2006, (the "Effective Date"), is entered into by and
between BioLineRx Ltd. ("BioLine"), Bar-Ilan Research
and Development Company Ltd. ("BIRAD") and Ramot at Tel Aviv
University Ltd. ("Ramot", and together with
BIRAD, the
"Licensors").

    

    WHEREAS,
BioLine and the Licensors entered into that certain Research and License
Agreement dated as of April 15, 2004 (the "Research and License
Agreement"); and

    

    WHEREAS,
BioLine and the Licensors entered into an amendment agreement dated June 2004
(the "First Amendment Agreement") to
amend the Research and License Agreement; and

    

    WHEREAS,
BioLine and the Licensors desire to further amend the Research and License
Agreement as set out herein;

    

    NOW,
THEREFORE, the parties agree as follows:

    

    1.
Capitalized terms used but not otherwise defined herein shall have the meanings
ascribed to them in the Research and License Agreement.

    

    2.
Section 1.21 of the Resarch and License Agreement shall be deleted in its
entirety and replaced with the following:

    

    "1.21
"Licensed Product" shall mean any
of the following:

    

    (i)
any therapeutic product that comprises, contains or incorporates Licensor
Technology; or

    (ii)
Any therapeutic product that comprises, contains, or incorporates any compound
that is covered by a Valid Patent Claim under the Joint Patent
Rights.

    

    3. The
following new Section 1 .41 shall be added following Section 1.40:

    

    "1.41
"Valid Patent Claim " shall mean a
claim of a Licensed Patent Right for as long as such claim shall not have
expired or been held invalid in a final non appealable court judgment or patent
office decision in the relevant jurisdiction, or an appeal for it has not been
filed within the time
allowed for an appeal.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    4.
The following shall be added at the end of the last sentence of section
5.1:

    

    "..., and
subject further, to the
rights of employees, students and other researchers of TAU and BIU to practice
and utilize such rights and licenses solely for academic research purposes
within TAU and BIU (the "Academic Research"). Notwithstanding the foregoing, any
in vivo experimentation
that may be included within the scope of
Academic Research that is conducted by, or on behalf of Ramot or BIRAD, shall
require the prior written approval of BioLine if and to the extent that such
research involves in vivo
experimentation of compounds that are currently being developed as
Licensed Products by BioLine, such approval not to be unreasonably delayed or
withheld. For the removal of doubt, Ramot, Tel Aviv University, BIRAD and BIU
shall not obtain funding for Academic Research from any party on terms that (i)
give such party any rights to the Licensed Technology that are inconsistent with
the rights granted to BioLine hereunder, or (ii) limit in any manner the scope
or terms of the license and rights granted to BioLine hereunder.

    

    5. Except
as amended pursuant to this Amendment Agreement, the terms of the Research and
License Agreement and the First Amendment Agreement shall remain in full force
and effect.

    

    [Remainder
of page intentionally left blank Signature page
follows.]

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    IN WITNESS WHEREOF, the
parties have caused this Agreement to be executed by their duly authorized
representatives as of the date first written above.

    

    
      	
              Ramot
      at Tel Aviv Univ ty Ltd.

            
	
              By:
      /s/ Ze’ev Weinfeld, Ph.D.

            
	
              Name:
      Ze’ev Weinfeld, Ph.D.

            
	
              Title:
      Executive Vice President, Business Development

            
	 
      
	
              BiolineRx
      Ltd.

            
	
              By:
      /s/ Yuri Shoshan

            
	
              Name:
      Yuri Shoshan

            
	
              Title:
      Vice President, Finance and Corporate Development

            
	 
      
	
              Bar-Ilan
      Research and Development

            
	
              By:
      /s/ Gabriel Kenan

            
	
              Name:
      Gabriel Kenan

            
	
              Title:
      C.E.O. Bar-Ilan Research & Development Company
  Ltd.

            

    

    

    We, the
undersigned, hereby confirm that we have read the Amendment Agreement,
that its
contents are acceptable to us and that we will act in accordance with its
terms.

    

    
      	
              /s/ lrit Gil-Ad

            	 
      
	
              Dr.lrit
      Gil-Ad

            	 
      
	 
      	 
      
	
              /s/ Abraham Weizman

            	 
      
	
              Professor
      Abraham Weizman

            	 
      
	 
      	 
      
	
              /s/ Ada Rephaeli

            	 
      
	
              Dr.
      Ada Rephaeli

            	 
      
	 
      	 
      
	
              /s/ Abraham Nudelman

            	 
      
	
              Professor
      Abraham Nudelman

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00178-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00178-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00178-of-00352.parquet"}]]